Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MK 2060

X
Drug Profile

MK 2060

Alternative Names: MK-2060

Latest Information Update: 29 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Anticoagulants; Antithrombotics; Monoclonal antibodies; Urologics
  • Mechanism of Action Factor XI inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Thrombosis
  • Phase I Renal failure

Most Recent Events

  • 15 Oct 2024 Merck Sharp & Dohme initiates phase I safety, pharmacokinetics, and pharmacodynamics trial (In volunteers (IV, infusion) in the US (NCT06582602)
  • 03 Sep 2024 Merck Sharp & Dohme plans a phase I safety, pharmacokinetics, and pharmacodynamics trial in healthy subjects (IV, infusion, ) in September 2024 (NCT06582602)
  • 15 Feb 2024 Merck Sharp & Dohme completes a phase-I trial in Renal failure (In adults, In the elderly) in Japan (NCT05769595),

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top